NCT06079476 is a Phase 4 clinical trial of Romosozumab in Postmenopausal Osteoporosis, sponsored by Amgen.

Who is sponsoring NCT06079476?

NCT06079476 is sponsored by Amgen.

What drugs are being tested in NCT06079476?

Interventions in NCT06079476: Romosozumab.

What condition does NCT06079476 study?

NCT06079476 studies Postmenopausal Osteoporosis.

Is NCT06079476 still recruiting?

NCT06079476 is currently completed. Last updated 3 November 2025.

Last reviewed 2025-11-03 · How we verify

NCT06079476

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

Completed Phase 4 Last updated 3 November 2025

What this trial tests

Phase 4 trial testing Romosozumab in Postmenopausal Osteoporosis in 100 participants. Completed in 18 October 2025.

Timeline

30 October 2023

Primary endpoint
18 October 2025

18 October 2025

Quick facts

Lead sponsor	Amgen
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	30 October 2023
Primary completion	18 October 2025
Estimated completion	18 October 2025
Sites	10 locations across India

Drugs / interventions tested

Romosozumab (romosozumab) — full drug profile →

Conditions studied

Postmenopausal Osteoporosis — all drugs for Postmenopausal Osteoporosis →

Sponsor

Amgen — full company profile →

Who can join

18 and older, female only, with Postmenopausal Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs.
He T, Qin L, Chen S, Huo S, et al · · 2025 · cited 20× · PMID 40307216 · DOI 10.1038/s41413-025-00424-1

Verify or expand the search:

Other trials of Romosozumab

Trials testing the same drug.

NCT07283887 — Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis · Phase 4 · recruiting
NCT07384104 — Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in He · Phase 1 · enrolling by invitation
NCT06558188 — Combined Anabolic Therapy · Phase 4 · recruiting
NCT05972551 — Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Oste · Phase 3 · recruiting
NCT05010590 — Anabolic Therapy in Postmenopausal Osteoporosis · Phase 4 · active not recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06079476 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 3 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06079476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing